Welcome to our dedicated page for Maze Therapeutics SEC filings (Ticker: MAZE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Maze Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Maze Therapeutics's regulatory disclosures and financial reporting.
Maze Therapeutics (MAZE) reported Q3 2025 results with a net loss of $30,087,000, reflecting higher R&D and G&A spending as programs advance. There was no license revenue in the quarter, versus $2,500,000 in Q3 2024.
Operating expenses rose to $32,965,000 (R&D $25,190,000; G&A $7,775,000). Interest and other income contributed $2,878,000. Year‑to‑date, the company recorded a net loss of $96,552,000, compared to net income in 2024 driven by one‑time license payments.
Liquidity strengthened significantly in 2025. Cash, cash equivalents and marketable securities totaled $383.9 million as of September 30, 2025. The company completed an IPO in February 2025 (8,750,000 shares at $16.00, net proceeds ~$127.8 million) and a September 10, 2025 private placement (4,000,002 shares at $16.25 and 5,231,090 pre‑funded warrants at $16.249, net proceeds ~$141.3 million). A $50 million revolving line was extended to June 2026. Shares outstanding were 48,119,444 as of November 3, 2025.
Maze Therapeutics, Inc. filed a current report to note it issued a press release with its financial results for the third quarter ended September 30, 2025.
The press release, dated November 6, 2025, is furnished as Exhibit 99.1 and is designated as “furnished,” not “filed,” limiting its treatment under certain securities law liability provisions.
Maze Therapeutics, Inc. filed a Rule 424(b)(3) prospectus covering the resale of up to 9,231,092 shares of common stock by selling stockholders. This includes 4,000,002 Initial Shares and up to 5,231,090 Warrant Shares issuable upon exercise of pre-funded warrants issued in a September 2025 private placement.
The company is not selling any securities in this prospectus and will not receive proceeds from sales by the holders. Upon any cash exercise of the pre-funded warrants (exercise price $0.001 per share), the company would receive the exercise price. The shares may be sold at market or negotiated prices through brokers, dealers, agents, or direct sales. The warrants include a 4.99% or 9.99% beneficial ownership cap. As context, shares outstanding were 48,076,885 as of September 30, 2025. Examples of registered resale amounts include Entities Affiliated with Baker Brothers 1,538,556 and Janus Henderson 1,230,769. Common stock trades on Nasdaq as MAZE.
Maze Therapeutics (MAZE): Form 4 insider activity
Affiliates of Third Rock Ventures reported a pro rata, for-no-consideration distribution of 1,600,000 shares of Maze Therapeutics common stock on November 4, 2025, noted with transaction code J and described as exempt under Rules 16a-13 and 16a-9. Following the distribution, the filing shows 4,473,958 shares beneficially owned directly and 950,800 shares beneficially owned indirectly, with relationships indicated including director and 10% owner statuses and standard beneficial ownership disclaimers among the TRV entities.
Maze Therapeutics (MAZE) reported an insider transaction by a director. On 10/23/2025, the reporting person made a gift of 28,423 shares of common stock, recorded at $0 as a no‑consideration transfer exempt under Rule 16b‑5.
Following the transaction, the filer beneficially owned 29,624 shares directly and 7,422 shares indirectly through the Charles J. Homcy Revocable Trust UA 11/4/1998, of which the reporting person is trustee.
Maze Therapeutics, Inc. (MAZE) filed a preliminary Form S-1 covering the resale of up to 9,231,092 shares of common stock by selling stockholders. The shares comprise 4,000,002 initial shares and up to 5,231,090 shares issuable upon exercise of pre-funded warrants issued in a September 10, 2025 private placement.
The company is not selling any securities in this offering and will not receive proceeds from stockholder sales; it would receive only the $0.001 per‑share exercise price if any pre-funded warrants are exercised for cash. Sales may occur from time to time after effectiveness at market or negotiated prices through brokers, underwriters, or direct sales.
Examples of per‑holder amounts include Entities Affiliated with Baker Brothers 1,538,556 and Entities Affiliated with Janus Henderson 1,230,769. Pre‑funded warrants include a 4.99% or 9.99% beneficial ownership cap. MAZE trades on Nasdaq Global Market under “MAZE.”
Maze Therapeutics, Inc. director Herve Hoppenot was granted a stock option on 10/06/2025 to buy 36,000 shares of common stock at an exercise price of $27.52 per share. The option vests monthly at 1/36 of the award beginning on 11/06/2025 and on each monthly anniversary thereafter, subject to continued service, and expires on 10/05/203536,000 options directly. The filing was signed by an attorney-in-fact on 10/07/2025.
Maze Therapeutics director Herve Hoppenot filed an Initial Statement of Beneficial Ownership (Form 3) reporting no securities beneficially owned as of 10/06/2025. The filing lists his role as a Director and was signed by an attorney-in-fact on 10/07/2025. The form shows no direct or indirect holdings and no derivative positions reported.
Maze Therapeutics appointed Mr. Hoppenot to the Board and named him Chairman effective October 6, 2025. As a non-employee director he will receive a pro rata portion of the $40,000 annual director retainer and a pro rata portion of the $30,000 annual chairman retainer for the remainder of the year under the companys existing policy. The Board also granted an option to purchase up to 36,000 shares of common stock (the Option Award), with 1/36th of the underlying shares vesting and becoming exercisable on each monthly anniversary of the Appointment Date, subject to continued service.
The arrangement combines cash retainer compensation paid pro rata for partial-year service with an equity award that vests monthly over 36 months, tying compensation to ongoing service while spreading equity delivery across a multi-year period.
Courtney Phillips, General Counsel and Corporate Secretary of Maze Therapeutics, acquired 22,000 restricted stock units (RSUs) on 09/22/2025. Each RSU converts to one share of common stock upon settlement, and the award shows 22,000 shares beneficially owned after the grant at a reported price of $0. The RSUs vest 50% on 09/01/2026 and 50% on 09/01/2027, contingent on continued service, and the units do not expire; they vest or are cancelled prior to vesting dates.